DK421687A - Vektorvirus, der baerer en heterolog dna-sekvens - Google Patents

Vektorvirus, der baerer en heterolog dna-sekvens

Info

Publication number
DK421687A
DK421687A DK421687A DK421687A DK421687A DK 421687 A DK421687 A DK 421687A DK 421687 A DK421687 A DK 421687A DK 421687 A DK421687 A DK 421687A DK 421687 A DK421687 A DK 421687A
Authority
DK
Denmark
Prior art keywords
dna sequence
heterologous dna
virus carrying
vector virus
tumour
Prior art date
Application number
DK421687A
Other languages
English (en)
Other versions
DK421687D0 (da
DK173755B1 (da
Inventor
Richard Lathe
Marie-Paule Kieny
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of DK421687D0 publication Critical patent/DK421687D0/da
Publication of DK421687A publication Critical patent/DK421687A/da
Application granted granted Critical
Publication of DK173755B1 publication Critical patent/DK173755B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK198704216A 1986-08-13 1987-08-12 Farmaceutisk komposition omfattende en viral vektor DK173755B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8611700A FR2602790B1 (fr) 1986-08-13 1986-08-13 Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante
FR8611700 1986-08-13

Publications (3)

Publication Number Publication Date
DK421687D0 DK421687D0 (da) 1987-08-12
DK421687A true DK421687A (da) 1988-02-14
DK173755B1 DK173755B1 (da) 2001-09-10

Family

ID=9338277

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198704216A DK173755B1 (da) 1986-08-13 1987-08-12 Farmaceutisk komposition omfattende en viral vektor

Country Status (9)

Country Link
EP (1) EP0259212B1 (da)
JP (2) JP2852515B2 (da)
AT (1) ATE101648T1 (da)
AU (1) AU619448B2 (da)
CA (1) CA1341241C (da)
DE (1) DE3789082T2 (da)
DK (1) DK173755B1 (da)
ES (1) ES2061520T3 (da)
FR (1) FR2602790B1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2222165B (en) * 1988-08-20 1992-06-17 Animal Health Inst Recombinant capripoxvirus
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6344445B1 (en) 1995-10-19 2002-02-05 Cantab Pharmaceutical Research Limited Herpes virus vectors and their uses
US6884430B1 (en) 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
DE69826124T3 (de) 1997-06-30 2007-10-11 Institut Gustave Roussy Verabreichung der nukleinsäure in den quergestreiften muskel
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
CA2416289C (en) 2000-07-21 2012-12-04 Essentia Biosystems, Inc. Multi-component biological transport systems
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
FR2829136B1 (fr) 2001-08-29 2006-11-17 Aventis Pharma Sa Derives lipidiques d'aminoglycosides
EP1479985B1 (en) 2002-01-17 2017-06-14 Alfa Laval Corporate AB Submerged evaporator comprising a plate heat exchanger and a cylindric casing where the plate heat exchanger is arranged
PT1497438E (pt) 2002-04-25 2010-02-04 Crucell Holland Bv Meios e métodos para a produção de vectores de adenovírus
US8790664B2 (en) 2008-09-05 2014-07-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Multimodular assembly useful for intracellular delivery
DK2382474T3 (da) * 2009-01-20 2015-04-07 Transgene Sa Opløselig icam-1 som biomarkør til forudsigelse af terapeutisk respons
FR3028527A1 (fr) 2014-11-13 2016-05-20 Pivert Identification de facteurs de transcription de yarrowia lipolytica
WO2016075314A1 (fr) 2014-11-13 2016-05-19 Institut National De La Recherche Agronomique Identification de facteurs de transcription de yarrowia lipolytica affectant la production de proteines
FR3081169B1 (fr) 2018-05-15 2020-06-19 Messenger Biopharma Substitution de la coiffe des arn messagers par deux sequences d'arn introduites a leur extremite 5'

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0795954B2 (ja) * 1982-11-30 1995-10-18 アメリカ合衆国 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
CA1282721C (en) * 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
AU623333B2 (en) * 1986-01-27 1992-05-14 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same

Also Published As

Publication number Publication date
AU619448B2 (en) 1992-01-30
EP0259212B1 (fr) 1994-02-16
JPS6349077A (ja) 1988-03-01
JPH09173061A (ja) 1997-07-08
DE3789082D1 (de) 1994-03-24
DE3789082T2 (de) 1994-09-01
JP2852515B2 (ja) 1999-02-03
AU7679787A (en) 1988-02-18
EP0259212A1 (fr) 1988-03-09
FR2602790A1 (fr) 1988-02-19
DK421687D0 (da) 1987-08-12
CA1341241C (fr) 2001-06-05
FR2602790B1 (fr) 1990-06-01
ES2061520T3 (es) 1994-12-16
ATE101648T1 (de) 1994-03-15
DK173755B1 (da) 2001-09-10

Similar Documents

Publication Publication Date Title
DK421687D0 (da) Vektorvirus, der baerer en heterolog dna-sekvens
ATE112802T1 (de) Herstellung von funktionellen menschlichen urokinasepolypeptiden.
DE3786592T3 (de) Transformation von Trichoderma.
DK143492A (da) Human-h2-praeprorelaxin, -prorelaxin og -relaxin samt polypeptid med relaxinaktivitet
DE10399037I2 (de) Rekombinante Virusproteine begleitet von lymphadenopathischem Sydrom und/oder "Acquired Immune Deficiency Syndrome" (AIDS).
KR860005020A (ko) 말 및 개의 인터페론의 제조방법
ATE162079T1 (de) Verwendung von antikörper enthaltenden präparationen zur immunsuppression
FI852683A0 (fi) Immunisk motverkan foer tumoerer och virus.
DK366483A (da) Gen, dna-transfervektor eller underenhed heraf, der koder for human preprorelaxin eller en underenhed deraf, fremgangsmaade til fremstilling af samme samt fremgangsmaade til fremstilling af human preprorelaxin eller en underenhed deraf
FI99116B (fi) Menetelmä valmistaa hevosen -interferonia
DK606285A (da) Vaccine mod rabies samt fremgangsmaade til fremstilling deraf
ATE108333T1 (de) Herstellung und verwendung von anti- helminthischen wirkstoffen und schutzantigenen.
FI853389L (fi) Tumoerlaekemedel och foerfarande foer dess framstaellning.
ATE136933T1 (de) Rekombinante hbsag hybridpartikel, die morphologische eigenschaften von hbsag-antigen haben und eine immunogene sequenz enthalten, die neutralisierende antikörper gegen hiv induziert oder die von diesen antikörpern erkannt ist, nukleotide sequenzen, die diese partikel codieren und sie enthaltende impfstoffe
DK513687D0 (da) Monoklonale antistoffer over for ifn-omega, fremgangsmaade til deres fremstilling og deres anvendelse til rensning samt paavisning af ifn-omega
ATE92333T1 (de) Arzneimittel zur intralesionsbehandlung von schuppenartigem zellkarzinomen mit rekombinantem human-alpha-interferon.
AT388848B (de) Praeparate zur verbesserung der gewichtszunahme von und der futterverwertung durch tiere(n)
IT8022130A0 (it) Processo per la preparazione disolfuri arilici e vinilici.
NO871737D0 (no) Rekombinant virus, polypeptid samt dna molekyl med kodingssekvens for dette polypeptid.
ATE52798T1 (de) Hepatitis-b-virus-gen enthaltendes rekombinantes plasmid, mit diesem rekombinanten plasmid transformierte hefe und herstellung von hepatitis-b-virus-oberflaechenantigen.

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed

Country of ref document: DK